ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (ACOR) (Nasdaq:ACOR) today announced its intention to offer, subject to market and other conditions, $300 million principal amount of convertible senior notes due 2021 (the "Notes") pursuant to an ... ...

40 people liked this